Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

Publication Type:

Journal Article

Source:

PloS one, Volume 7, Issue 11, p.e48787 (2012)

Keywords:

2012, Center-Authored Paper, Clinical Research Division, January 2013, Public Health Sciences Division, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, Specimen Processing Core Facility

Abstract:

Sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, inhibits the mitogen-activated protein kinase pathway that is activated in most uveal melanoma tumors. This phase II study was conducted by the SWOG cooperative group to evaluate the efficacy of sorafenib in combination with carboplatin and paclitaxel (CP) in metastatic uveal melanoma.